Migraine drug could soothe stubborn facial pain
NCT ID NCT07250984
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small study tests whether eptinezumab, a drug used for migraines, can reduce pain in people with atypical facial pain that hasn't responded to other treatments. Ten participants will receive two intravenous infusions three months apart. The main goal is to see if the drug improves daily functioning, measured by a migraine disability questionnaire.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eptinezumab (ACMP)
- What this could lead to
- If it works, this could point toward a new treatment option for people with persistent facial pain that is hard to treat.
- What could go wrong
- This is a very small, early-stage trial with only 10 participants. It may not show clear benefit, and results may not apply to everyone with facial pain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL RESISTANT FACIAL PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pain Therapy Clinic of University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a symptom registry unmask hidden migraine variants?
- Can a simple joint wash beat botox for jaw pain?
- Which dry needling method best eases jaw pain? a Head-to-Head trial
- New device combo aims to quiet jaw pain without drugs
- New laser zaps TMJ pain in small trial
- Could a dab of antibiotic gel replace pills after wisdom tooth removal?